Natural Insomnia Program

Latest Treatment of Insomnia

Get Instant Access

1. G. Vogel, Studies in psychophysiology of dreams. III. The dream of narcolepsy, Arch Gen Psychiatry. 3,

2. M. Carskadon, W. Dement, M. Mitler, T. Roth, P. Westbrook and S. Keenan, Guidelines for the Multiple

Sleep Latency Test (MSLT): a standardized measure of sleepiness, Sleep. 9, 519-524 (1986).

3. L. de Lecea, T. S. Kilduff, C. Peyron, X. Gao, P. E. Foye, P. E. Danielson, C. Fukuhara, E. L. Battenberg, V.

T. Gautvik, F. S. Bartlett, 2nd, W. N. Frankel, A. N. van den Pol, F. E. Bloom, K. M. Gautvik and J. G. Sutcliffe, The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity, Proc Natl Acad Sci U SA. 95, 322-7 (1998).

4. T. Sakurai, A. Amemiya, M. Ishii, I. Matsuzaki, R. M. Chemelli, H. Tanaka, S. C. Williams, J. A.

Richardson, G. P. Kozlowski, S. Wilson, J. R. Arch, R. E. Buckingham, A. C. Haynes, S. A. Carr, R. S. Annan, D. E. McNulty, W. S. Liu, J. A. Terrett, N. A. Elshourbagy, D. J. Bergsma and M. Yanagisawa, Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior, Cell. 92, 573-85 (1998).

5. L. Lin, J. Faraco, R. Li, H. Kadotani, W. Rogers, X. Lin, X. Qiu, P. J. de Jong, S. Nishino and E. Mignot, The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene, Cell. 98, 365-76 (1999).

6. R. M. Chemelli, J. T. Willie, C. M. Sinton, J. K. Elmquist, T. Scammell, C. Lee, J. A. Richardson, S. C.

Williams, Y. Xiong, Y. Kisanuki, T. E. Fitch, M. Nakazato, R. E. Hammer, C. B. Saper and M. Yanagisawa, Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation, Cell. 98, 437-51 (1999).

7. S. Nishino, B. Ripley, S. Overeem, G. J. Lammers and E. Mignot, Hypocretin (orexin) deficiency in human narcolepsy, Lancet. 355, 39-40 (2000).

8. C. Peyron, J. Faraco, W. Rogers, B. Ripley, S. Overeem, Y. Charnay, S. Nevsimalova, M. Aldrich, D.

Reynolds, R. Albin, R. Li, M. Hungs, M. Pedrazzoli, M. Padigaru, M. Kucherlapati, J. Fan, R. Maki, G. J. Lammers, C. Bouras, R. Kucherlapati, S. Nishino and E. Mignot, A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains, Nat Med. 6, 991-997 (2000).

9. T. C. Thannickal, R. Y. Moore, R. Nienhuis, L. Ramanathan, S. Gulyani, M. Aldrich, M. Cornford and J. M.

Siegel, Reduced number of hypocretin neurons in human narcolepsy, Neuron. 27, 469-74. (2000).

10. C. Guilleminault. (1976). Cataplexy. In Proceedings of the First International Symposium on Narcolepsy.

(Guilleminault, C., Dement, W. & Passouant, P., eds.), pp. 125-144. Spektrum Publications, New York.

11. R. Broughton, V. Valley, M. Aguirre, J. Roberts, W. Suwalski and W. Dunham, Excessive daytims sleepiness and the pathophysiology of narcolepsy-cataplexy: a laboratory perspective, Sleep. 9, 205-215 (1986).

12. C. Knecht, J. Oliver, R. Redding, R. Selcer and G. Johnson, Narcolepsy in a dog and a cat., J Am Vet Med

13. Y. Honda, A. Asake, Y. Tanaka and T. Juji, Discrimination of narcolepsy byusing genetic markers and

14. S. Nishino and E. Mignot, Pharmacological aspects of human and canine narcolepsy, Prog Neurobiol. 52,

15. E. Mignot, X. Lin, J. Arrigoni, C. Macaubas, F. Olive and J. Hallmayer, DQB1*0602 and DQA1*0102

(DQ1) are better markers than DR2 for narcolepy in Causcasians and Black Americans, Sleep. 17, S60-7 (1994).

16. E. Mignot, A. Renaud, S. Nishino, J. Arrigoni, C. Guilleminault and W. Dement, Canine cataplexy is preferentially controlled by adrenergic mechanisms: evidence using monoamine selectvie uptake inhibitors and release enhancers, Psychopharmacology. 113, 76-82 (1993).

17. S. Nishino, J. Mao, R. Sampathkumaran, J. Shelton and E. Mignot, Increased dopaminergic transmission mediates the wake-promoting effects of CNS stimulants, Sleep Res Online. 1, 49-61 (1998).

18. E. Mignot, L. Lin, W. Rigers, Y. Honda, X. Qiu, X. Lin, M. Okun, H. Hohjoh, T. Miki, S. Hsu, M. Leffell,

F. Grumet, M. Fernandez-Vina, M. Honda and N. Risch, Complex HLA-DR and -DQ interactions confer risk of narcolepsy-cataplexy in three ethnic groups, Am J Hum Genet. 68, 686-699 (2001).

19. J. Hara, C. Beuckmann, T. Nambu, J. Willie, R. Chemelli, C. Sinton, F. Sugiyama, K. Yagami, K. Goto, M.

Yanagisawa and T. Sakurai, Genetic ablation of orexin neurons in mice results in narcolespy, hypophagia, and obesity, Neuron. 30, 345-354 (2001).

20. K. Matsuki, F. Grumet, X. Lin, C. Guilleminault, W. Dement and E. Mignot, DQ rather than DR gene marks susceptibility to narcolepsy, Lancet. 339, 1052 (1992).

21. C. Peyron, J. Faraco and W. Rogers, A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in humans narcoleptic brains, Nat Med. 6, 991-997 (2000).

22. T. Thannickal, R. Moore and R. Nienhuis, Reduced number of hypocretin neurons in human narcolepsy,

23. J. Emard, J. Thouez and D. Gauvreau, Neurodegenerative diseases and risk factors: a literature review, Soc

24. S. Overeem, E. Mignot, J. vanDijk and G. Lammers, Narcolepsy: clinical features, new pathophysiologic insights, and future perspectives, J Clin Neurophysiol. 18, 78-105 (2001).

25. Y. Dauvilliers, M. Billiard and J. Montplaisir, Clinical aspects and pathophysiology of narcolepsy, Clin

Neurophysiol. 114, 2000-2017 (2003).

26. S. Taheri, J. Zeitzer and E. Mignot, The role of hypocretins (orexins) in sleep regulation and narcolepsy,

Annu Rev Neurosci. 25, 283-313 (2002).

27. E. Mignot, A Commentary on the Neurobiology of the Hypocretin/Orexin System, Neuropsychopharmacology. 25, S5-S13 (2001).

28. C. Bassetti, M. Gugger, M. Bischof, J. Mathis, C. Sturzenegger, E. Werth, B. Radanov, B. Ripley, S.

Nishino and E. Mignot, The narcoleptic borderland: a multimodal diagnostic approach including cerebrospinal fluid levels of hypocretin-1 (orexin A), Sleep Med. 4, 7-12 (2003).

29. E. Mignot, Genetic and familial aspects of narcolepsy, Neurology. 50, S16-S22 (1998).

30. Y. Dauvilliers, S. Maret, C. Bassetti, B. Carlander, M. Billiard, J. Touchon and M. Tafti, A monozygotic twin pair discordant for narcolepsy and CSF hypocretin-1, Neurology. 62, 2137-2138 (2004).

31. R. Khatami, S. Maret, E. Werth, J. Retey, D. Schmid, F. Maly, M. Tafti and C. Bassetti, Monozygotic twins concordant for narcolepsy-cataplexy without any detectable abnormality in the hypocrtein (orexin) pathways, Lancet. 363, 1199-1200 (2004).

32. M. Honda, Y. Honda, S. Uchida, S. Miyazaki and K. Tokunaga, Monozygotic twins incompletely concordant for narcolepsy, Biol Psychiatry. 49, 943-947 (2001).

33. M. Mitler, O. Soave and W. Dement, Narcolepsy in several dogs, J Am Vet Med Assoc. 168, 1036-1038

34. L. Lin, J. Faraco and R. Li, The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin

(orexin) receptor 2 gene, Cell. 98, 365-376 (1999).

35. M. Hungs, J. Fan, L. Lin, X. Lin, R. Maki and E. Mignot, Identification and functional analysis of mutations in the hypocretin (orexin) genes of narcoleptic canines, Genome Res. 11, 531-539 (2001).

36. B. Ripley, N. Fujiki and M. Okura, Hypocretin levels in sporadic and familial cases of canine narcolepsy,

37. L. Lin, M. Hungs and E. Mignot, Narcolepsy and the HLA region, J Neuroimmunology. 117, 9-20 (2001).

38. J. Wagner, R. Storb, B. Storer and E. Mignot, DLA-DQB1 alleles and bone marrow transplantation experiments in narcoleptic dogs, Tissue Antigens. 56, 223-31 (2000).

39. D. Chabas, S. Taheri, C. Renier and E. Mignot, The Genetics of Narcolepsy, Annu Rev Genomics Hum

40. S. Overeem, T. Scammell and G. Lammers, Hypocretin/orexin and sleep: implications for the pathophysiology and diagnosis of narcolepsy, Curr Opin Neurology. 15, 739-745 (2002).

41. M. Gencik, N. Dahmen, S. Wieczorek and M. Kasten, A prepro-orexin gene polymorphism is associated wtih narcolepsy, Neurology. 56, 115-117 (2001).

42. T. Juji, M. Satake, Y. Honda and Y. Doi, HLA antigens in Japanese patients with narcolepsy, Tissue

43. W. H. O. (WHO), WHO: Nomenclature Committee for factors of the HLA system, 1989, Immunogenetics.

44. S. Neely, R. Rosenberg, J. Spire, J. Antel and B. Arnason, HLA antigens in narcolepsy, Neurology. 37,

45. S. Kuwata, K. Tokunaga, F. Jin, T. Juji, T. Sasaki and Y. Honda, Letter to the editor after Dr. Aldrich's review on narcolepsy, NEJM. 324, 271-2 (1991).

46. K. Matsuki, F. Grumet, X. Lin, C. Guilleminault, W. Dement and E. Mignot, HLA DQB1*0602 rather than

HLA DRw15 (DR2) is the disease susceptibility gene in Black narcolepsy, Lancet. 339, 1052 (1992).

47. E. Mignot, A. Kimura, A. Lattermann, X. Lin, S. Yasunuga and G. Mueller-Eckhardt, Extensive HLA class

II studies in 58 non DRB1*15 (DR2) narcoleptic patients with cataplexy, Tissue Antigens. 49, 329-41 (1997).

48. E. Mignot, R. Hayduk, J. Black and F. Grumet, HLA DQB1*0602 is associated with cataplexy in 509

narcoleptic patients, Sleep. 20, 1012-1020 (1997).

49. Z. Pelin, C. Guilleminault, N. Risch, F. Grumet and E. Mignot, HLA DQB1*0602 homozygosity increases relative risk for narcolepsy but not disease severity in two ethnic groups. US Modafinil in Narcolepsy Multicenter Study Group, Tissue Antigens. 51, 96-100 (1998).

50. Y. Dauvilliers, M. Bazin, B. Ondze, O. Bera, M. Bazin and A. Besset, Severity of narcolepsy among Frech of different ethnic origins (South of France and Martinique). Sleep. 25, 50-5 (2002).

51. E. Mignot, J. Meeyan, F. Grumet, J. Hallmeyer, C. Guilleminault and P. Hesla, HLA class II and narcolepys in thirty-three multiplex families, Sleep Res Online. 25, 303 (1996).

52. H. Koch, I. Craig, M. Dahlitz, R. Denney and D. Parkes, Analysis of the monoamine oxidase genes and the

Norrie disease gene locus in narcolepsy, Lancet. 353, 645-646 (1999).

53. Y. Dauvilliers, E. Neidhart, M. Lecendreux, M. Billiard and M. Tafti, MAO-A and COMT polymorphisms and gene effects in narcolepsy, Mol Psychiatry. 6, 367-72 (2001).

54. H. Hohjoh, T. nakayama, J. Ohashi, T. Miyagawa, H. Tanaka, T. Akaza, Y. Honda, T. Juji and K.

Tokunaga, Signficant association of a single nucleotide polymorphism in the tumor necrosis factor-alpha (TNF-alpha) gene promoter with human narcolepsy, Tissue Antigens. 54, 138-145 (1999).

55. S. Shoham, D. Davenne, A. Cady, C. Dinarello and J. Krueger, Recombinant tumor necrosis factor and interleukin 1 enhance slow-wave sleep, Am J Physiol. 253, 42-9 (1987).

56. H. Hohjoh, N. Terada, M. Kawashima, Y. Honda and K. Tokunaga, Significant association of the tmor necrosis factor receptor 2 (TNFR2) gene wiht human narcolepsy, Tissue Antigens. 56, 446-48 (2000).

57. Y. Dauvilliers, B. Carlander, N. Molinari, A. Desautels, M. Okun, M. Tafti, J. Montplaisir, E. Mignot and

M. Billiard, Month of birth as a risk factor for narcolepsy, Sleep. 26, 663-5 (2003).

58. S. Nishino, B. Ripley and S. Overeem, Hypocretin (orexin) deficiency in human narcolepsy, Lancet. 355,

59. E. Mignot, G. Lammers, B. Ripley, M. Okun, S. Nevsimalova, S. Overeem, J. Vankova, J. Black, J. Harsh,

C. Bassetti, H. Schrader and S. Nishino, The role of CSF hypocretin measurements in the diagnosis of narcolepsy and other hypersomnias, Arch Neurol. 59, 1553-1562 (2002).

60. S. Nishino, N. Fujiki and B. Ripley, Decreased brain histamine content in hypocretin/orexin receptor-2

mutated narcoleptic dogs, Neurosci Lett. 313, 125-128 (2001).

61. T. Kanbayashi, T. Kodama, H. Kondo, S. Satoh, N. Miyazaki, K. Kuroda, M. Abe, S. Nishino, Y. Inoue and

T. Shimizu, CSF Histamine and Noradrenaline Contest in Narcolepsy and Other Sleep Disorders, Sleep. 27, A236 (2004).

62. Z. Huang, W. Qu and W. Li, Arousal effect of orexin A depends on activation of the histaminergic system,

Proc Natl Acad Sci USA. 98, 9965-9970 (2001).

63. C. Saper, T. Chou and T. Scammell, The sleep switch: hypothalamic control of sleep and wakefulness,

Trends Neurosci. 24, 726-731 (2001).

64. A. Schuld, J. Hebebrand, F. Geller and T. Pollmacher, Increased body-mass index in patients with narcolepsy, Lancet. 355, 1274-1275 (2000).

65. M. Okun, L. Lin, Z. Pelin, S. Hong and E. Mignot, Clinical aspects of narcolepsy-catalexy across ethnic groups, Sleep. 25, 27-35 (2002).

66. A. Yamanaka, C. Beuckmann and J. Willie, Hypothalamic orexin neurons regulate arousal according to energy balance in mice, Neuron. 38, 701-13 (2003).

67. M. Aldrich, R. Chervin and B. Malow, Value of the multiple sleep latency test (MSLT) for the diagnosis of narcolepsy, Sleep. 20, 620-629 (1997).

68. A. Moscovitch, M. Pertinen and C. Guilleminault, The positive diagnosis of narcolepsy and narcolepsy's borderland, Neurology. 43, 55-60 (1993).

69. R. Salomon, B. Ripley, J. Kennedy, B. Johnson, D. Schmidt, J. Zeitzer, S. Nishino and E. Mignot, Diurnal variation of cerebrospinal fluid hypocretin-1 (Orexin-A) levels in control and depressed subjects, Biol Psychiatry. 54, 96-104 (2003).

70. Y. Yoshida, N. Fujiki, T. Nakajima, B. Ripley, H. Matsumura, H. Yoneda, E. Mignot and S. Nishino,

Fluctuation of extracellular hypocretin-1 (orexin A) leves in the rat in relation to the light-dark cycle and sleep-wake activities, Eur J Neurosci. 14, 1075-1081 (2001).

71. M. Dalal, A. Schuld, M. Haack, M. Uhr, P. Geisler, I. Eisensehr, S. Noachtar and T. Pollmacher, Normal plasma levels of orexin A (hypocretin-1) in narcoleptic patients, Neurology. 56, 1749-1751. Erraturm in : Neurology 2002; 58:334. (2001).

72. N. Igarashi, K. Tatsumi, A. Nakamura, S. Sakao, Y. Takiguchi, T. Nishikawa and T. Kuriyama, Plasma orexin-A levels in obstructive sleep apnea-hypopnea syndrome, Chest. 124, 1381-1385 (2003).

73. S. Sakurai, T. Nishijima, Z. Arihara and K. Takahashi, Plasma orexin-A levels in obstructive sleep apnea-

hypopnea syndrome, Chest. 125, 1963 (2004).

74. S. Taheri, J. M. Zeitzer and E. Mignot, The role of hypocretins (orexins) in sleep regulation and narcolepsy,

Annu Rev Neurosci. 25, 283-313 (2002).

75. S. Higuchi, A. SUsui, M. Murasaki, S. Matsushita, N. Nishioka, A. Yoshino, T. Matsui, H. Muraoka, Y.

Ishizuka, S. Kanba and T. Sakurai, Plasma orexin-A lower is lower in patients with narcolepsy, Neurosci Lett. 318, 61-64 (2002).

76. E. Karteris, J. Chen and H. Randeva, Expression of human prepro-orexin and signaling charcteristics or orexin receptors in the male reproductive system, J Clin Endocrinol Metab. 89, 1381-1385 (2004).

77. L. Krahn, VS, L. Oliver, B. Boeve and M. SIlber, Hypocretin (orexin) levels in cerebrospinal fluid of patients with narcolepsy: relationship to cataplexy and HLA DQB1*0602 status, Sleep. 25, 733-736 (2002).

78. T. Kanbayashi, Y. Inoue and S. Chiba, CSF hypocretin-1 (orexin A) concentrations in narcolepsy with and without cataplexy and idiopathic hypersomnia, J Sleep Res. 11, 91-93 (2002).

79. M. Dalal, A. Schuld and T. Pollmacher, Undetectable CSF level of orexin A (hypocretin-1) in a HLA-DR2

negative patient with narcolepsy-cataplexy, J Sleep Res. 11, 273 (2002).

80. E. Mignot, W. Chen and J. Black, On the value of measuring CSF hypocretin-1 in diagnosing narcolepsy,

81. B. Ripley, S. Overeem and N. Fujiki, CSF hypocretin/orexin levels in narcolepsy and other neurological conditions, Neurology. 57, 2253-2258 (2001).

82. C. Guilleminault, K. FAull, L. Miles and J. van den Hoed, Posttraumatic excessive daytime sleepiness: a review of 20 patients, Neurology. 33, 1584-1589 (1983).

83. R. Gledhill, P. Bartel, Y. Yoshida, S. Nishino and T. Scammell, Narcolepsy caused by acute disseminated encephalomyelitits, Arch Neurol. 61, 758-60 (2004).

84. I. Rubinstein, T. Gray, H. Moldofsky and V. Hoffstein, Neurosarcoidosis associated with hypersomnolence treated with corticosteroids and brain irradiation, Chest. 94, 205-6 (1988).

85. G. Rosen, A. Bendel, J. Neglia, C. Moertel and M. Mahowald, Sleep in children with neoplasms of the central nervous system: case review of 14 children, Pediatrics. 112, e46-54 (2003).

86. A. Autret, B. Lucas, K. Mondon, C. Hommet, P. Corcia, D. Saudeau and B. de Toffol, Sleep and brain lesions: a critical review of the literature and additional new cases, Neurophysiol Clin. 31, 356-75 (2001).

87. J. Arii, T. Kanbayashi and Y. Tanabe, A hypersomnolent girl with decreased CSF hypocretin level afte removal of a hypothalamic tumor, Neurology. 56, 1775-1776 (2001).

88. T. Scammell, S. Nishino, E. Mignot and C. Saper, Narcolepsy and low CSF orexin (hypocretin)

concentration after a diencephalic stroke, Neurology. 56, 1751-1753 (2001).

89. J. Vankova, I. Stepanova, R. Jech, M. Elleder, L. Ling, E. Mignot, S. Nishino and S. Nevsimalova, Sleep disturbances and hypocretin deficiency in Niemann-Pick disease type C, Sleep. 26, 427-430 (2003).

90. H. Fryssira, S. Kountoupi, J. Delaunoy and L. Thomaidis, A female with Coffin-Lowry syndrome and

"cataplexy", Genet Couns. 13, 405-9 (2002).

91. J. Parkes, Genetic factors in human sleep disorders with special reference to Norrie disease, Prader-Willi syndrome and Moebius syndrome, J Sleep Res. 8S, 14-22 (1999).

92. T. Kanbayashi, M. Abe, S. Fujimoto, T. Miyachi, T. Takahashi, T. Yano, Y. Sawaishi, J. Arii, G. Szilagyi and T. Shimizu, Hypocretin deficiency in Niemann-Pick type C with cataplexy, Neuropediatrics. 34, 5253 (2003).

93. J. Martinez-Rodriguez, L. Lin, A. Iranzo, D. Genis, M. Marti, J. Santamaria and E. Mignot, Decreased hypocretin-1 (Orexin-A) levels in the cerebrospinal fluid of patients with myotonic dystrophy and excessive daytime sleepiness, Sleep. 26, 287-290 (2003).

94. J. Wisor, S. Nishino, I. Sora, G. Uhl, E. Mignot and D. Edgar, Dopaminergic role in stimulant-induced wakefulness, J Neurosci. 21, 1787-1794 (2001).

95. Xyrem approved for muscle problems in narcolepsy, FDA Consum. 36, 7 (2002).

96. B. Carlander, J. Eliaou and M. Billiard, Autoimmune hypothesis in narcolepsy, Neurophysiol Clin. 23, 15

97. E. Mignot, M. Tafti, W. Dement and F. Grumet, Narcolepsy and immunity, Adv Neuroimmunol. 5, 23-37

98. D. Hinze-Selch, T. Wetter, Y. Zhang, H. Lu and E. Albert, In vivo and in vitro immune variables in patients with narcolespy and HLA-DR2 matched controls, Neurology. 50, 1149-1152 (1998).

99. M. Hecht, L. Ling, C. Kushida, D. Umetsu, S. Taheri, M. Einen and E. Mignot, Report of a case of immunosuppression with prednisone in an 8-year old boy with an acute onset of hypocretin-deficiency narcolepsy, Sleep. 26, 809-810 (2003).

100. M. Lecendreux, S. Maret, C. Bassetti, M. Mouren and M. Tafti, Clinical efficacy of high-dose intravenous immunoglobulins near the onset of narcolepsy in a 10-year-old boy, J Sleep Res. 12, 347-8 (2003).

101. J. John, M. Wu and J. Siegel, Systemic administration of hypocretin-1 reduces catapexy and normalizes sleep and waking durations in narcoleptic dogs, Sleep Res Online. 3, 23-28 (2000).

102. S. Nishino, N. Fujiki, Y. Yoshida and E. Mignot, The effects of hypocretin-1 in hypocretin receptor-2 mutated and hypocretin deficient narcoleptic dogs, Sleep. 26, A287 (2003).

103. Y. Yoshida, N. Fujiki, R. Maki, D. Schwarz and S. Nishino, Differential kinetics of hypocretins in the cerebrospinal fluid after intracerebroventricular administration in rats, Neurosci Lett. 346, 182-6 (2003).

Was this article helpful?

0 0
Sleep Like A PRO

Sleep Like A PRO

Learning About How To Sleep Like A PRO Can Have Amazing Benefits For Your Life And Success. Learn About Mastering Your Sleep Patterns For Maximum Productivity To Create Amazing Results!

Get My Free Ebook

Post a comment